P797: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF COMBINATION POZELIMAB AND CEMDISIRAN THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO SWITCH FROM ECULIZUMAB

Published 2023 View Full Article

Authors

Keywords

Journal

HemaSphere

Volume 7, Issue S3, Pages e6873083

Publisher

Ovid Technologies (Wolters Kluwer Health)

Online

2023-08-22

DOI

10.1097/01.hs9.0000970092.68730.83

Ask authors/readers for more resources

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

HemaSphere

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Create your own webinar

Ask a Question. Answer a Question.